Quantcast
Last updated on April 19, 2014 at 7:10 EDT

Latest Opioids Stories

2012-08-09 10:26:11

RALEIGH, N.C., Aug. 9, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 with the U.S. Securities and Exchange Commission. In connection therewith, BDSI is providing a review of its recent achievements in 2012, as well as an update on business operations and upcoming milestones for the balance of the year. (Logo:...

2012-08-09 06:26:48

COSTA MESA, Calif., Aug. 9, 2012 /PRNewswire/ -- Integrated Prescription Solutions (IPS), one of the country's fastest growing Prescription Benefit Management providers, announced the appointment of Dr. Avrom Gart, M.D. as Medical Director and head of its Pharmacy and Therapeutics (P&T) Committee. Dr. Gart oversees Physicians and Surgeons Network, a URAC accredited Physician Review Organization (PRO) consisting of more than 100 physician reviewers and the IPS P&T Committee....

2012-08-08 02:28:21

LONDON, Aug. 8, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by...

2012-08-08 02:27:15

RALEIGH, N.C., Aug. 8, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference. The presentation is scheduled for Wednesday, August 15, 2012 at 9:45 a.m. Eastern Time, at the Le Parker Meridien in New York City. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on BDSI's...

2012-08-07 02:28:40

PITTSBURGH, Aug. 7, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair® Tablets. Mylan also received final FDA approval for its ANDA for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Merck's Singulair®...

2012-08-06 10:24:51

CUPERTINO, Calif., Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2012. Total revenues were $4.8 million for the three months ended June 30, 2012 as compared to $7.8 million for the three months ended June 30, 2011. Net loss for the three months ended June 30, 2012 was $4.3 million, compared to a net loss of $5.2 million for the same period in 2011. (Logo:...

2012-08-03 23:00:28

The US FDA announced on its June 6th, 2012 enforcement report that J&J recalled more than 53,000 Duragesic (Fentanyl Transdermal System) patches because of crystallization. Fentanyl (brand names Duragesic, Onsolis and others) is a potent synthetic narcotic analgesic used to treat breakthrough cancer pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic. According to court documents, on January 3rd, 2012, a California man, Jose Campuzano filed a lawsuit...

2012-08-02 02:31:41

RALEIGH, N.C. and CHADDS FORD, Pa., Aug. 2, 2012 /PRNewswire-FirstCall/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Endo Health Solutions Inc. (Nasdaq: ENDP) today announced the initiation of the Phase 3 clinical program for BEMA Buprenorphine for the treatment of moderate to severe chronic pain. The Phase 3 program will consist of two efficacy studies, one in opioid naive and one in opioid experienced subjects. Both studies are anticipated to be completed by...

2012-08-01 23:02:31

Penn researcher calls for additional strategies to properly weigh benefits, risks of prescribing painkillers A new risk management plan from the U.S. Food and Drug Administration to help clinicians properly prescribe drugs with addiction potential aims to help reduce the growing epidemic of opioid abuse in the United States. With deaths associated with these drugs, often sold illegally, now reaching toward 14,000 each year — including the fatal shootings of two Philadelphia teenagers...

2012-08-01 06:22:32

NEW YORK, Aug. 1, 2012 /PRNewswire/ -- The American Society of Interventional Pain Physicians (ASIPP), a national medical society of over 4,000 members, has released its "Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain." A multidisciplinary panel of 55 medical experts drafted this comprehensive two-part guideline to improve patient care, curtail the abuse of opioids without jeopardizing non-cancer pain management treatments, and improve understanding among law...